In a 30-year-old woman with ankylosing spondylitis receiving certolizumab pegol (Cimzia) who now has scalp dermatitis, papular‑pustular rash on the torso and limbs, and vesicular (dyshidrotic) rash on the palms, what is the most likely diagnosis and what immediate management steps should be taken?

Certolizumab-Induced Paradoxical Cutaneous Reactions: Immediate Management Required

This patient is experiencing paradoxical cutaneous reactions to certolizumab pegol (Cimzia), most likely representing drug-induced psoriasiform eruption with possible palmoplantar pustulosis, and you should immediately discontinue Cimzia and initiate high-potency topical corticosteroids while arranging urgent dermatology consultation and infectious disease workup.

Clinical Reasoning

The temporal relationship is highly suggestive: maintenance Cimzia injection 2 weeks ago followed by eruption of multiple distinct rashes. TNF inhibitors, including certolizumab, are well-documented to cause paradoxical inflammatory skin reactions despite being used to treat inflammatory conditions 1.

Key Diagnostic Features Present:

• Scalp dermatitis (erythematous, scaly patches) - consistent with seborrheic dermatitis-like reaction seen with TNF inhibitors
• Papular/pustular trunk/limb rash - classic presentation of TNF inhibitor-induced psoriasiform eruption 2
• Vesicular palmar rash - highly suspicious for palmoplantar pustulosis, a recognized complication of certolizumab 3
• Timing: 9 months into therapy (rash can be delayed, appearing after several months) 4
• Progression despite antihistamines - rules out simple allergic reaction

Immediate Management Algorithm

Step 1: Rule Out Serious Infections (URGENT - Within 24 Hours)

The FDA label explicitly warns that certolizumab "can lower the ability of your immune system to fight infections" 1. You must exclude:

• Complete blood count with differential - look for neutropenia, lymphopenia, or leukocytosis
• Blood cultures if any fever develops
• HSV/VZV PCR from vesicles (already obtained - good)
• Bacterial culture from pustules - rule out superinfection
• Chest X-ray - exclude pulmonary infection given mild headache and chronic mild tonsillar erythema
• Inflammatory markers (CRP, ESR) - establish baseline

Critical pitfall: The mild tonsillar erythema present since Cimzia initiation could represent chronic immunosuppression-related colonization. Any fever, systemic symptoms, or worsening requires immediate hospitalization 1.

Step 2: Discontinue Certolizumab Immediately

Hold Cimzia now. The evidence is clear:

• Certolizumab-induced psoriasiform eruptions are well-documented 2
• Palmoplantar pustulosis triggered by certolizumab has been reported, particularly in patients with genetic predisposition 3
• The FDA label mandates discontinuation for "serious infection" and warns about skin changes 1

While one case report showed improvement with topical therapy alone 2, that patient had localized disease. Your patient has three distinct rash patterns suggesting more severe systemic reaction.

Step 3: Initiate Dermatologic Treatment

Immediate topical therapy:

• High-potency topical corticosteroid (e.g., clobetasol 0.05% ointment) to trunk/limb lesions twice daily 4, 2
• Scalp: Betamethasone valerate 0.1% lotion or clobetasol shampoo
• Palms: Clobetasol ointment under occlusion at night
• Emollients liberally to all affected areas

Oral therapy:

• Continue loratadine 10 mg daily for pruritus
• Consider adding oral antihistamine with sedating properties (hydroxyzine 25-50 mg at bedtime) for severe itch 2

Do NOT start systemic corticosteroids yet - this could mask infection and complicate diagnosis 4.

Step 4: Urgent Dermatology Consultation (Within 48-72 Hours)

Dermatology should:

• Confirm diagnosis with skin biopsy if diagnosis uncertain (look for subcorneal pustules, neutrophilic infiltration) 3, 5
• Assess for progression to severe reactions (Stevens-Johnson Syndrome/TEN, DRESS) - though current presentation doesn't suggest this 4
• Consider phototherapy if topical therapy insufficient 3

Step 5: Coordinate Rheumatology for Alternative AS Therapy

Do not restart certolizumab. For active ankylosing spondylitis after TNF inhibitor failure, the 2019 ACR/ASAS guidelines recommend 6:

First-line alternatives:

1. Switch to IL-17 inhibitor (secukinumab or ixekizumab) - strongly recommended 6, 7
2. Switch to different TNF inhibitor - conditionally recommended, but carries risk of recurrent paradoxical reaction
3. JAK inhibitor (tofacitinib, upadacitinib) - strongly recommended when biologics contraindicated 6, 7

Specific recommendation for this patient: Given the severe cutaneous reaction, IL-17 inhibitor (secukinumab or ixekizumab) is preferred as first choice after skin clearance 6, 7. However, note that IL-17 inhibitors can also rarely cause pustular reactions 5, so close dermatologic monitoring is mandatory.

Alternative if IL-17 inhibitors fail or contraindicated: Upadacitinib (JAK inhibitor) has shown efficacy in AS and successfully treated a case of secukinumab-induced pustular eruption 5.

What You Missed

Critical Omissions in Your Assessment:

1. No assessment for systemic infection - With immunosuppression, the "mild" tonsillar erythema and "light headache" could herald serious infection 1
2. No documentation of lymphadenopathy - essential to rule out lymphoma (increased risk with TNF inhibitors) 1
3. No hepatosplenomegaly check - hepatosplenic T-cell lymphoma is rare but fatal complication 1
4. No assessment of other TNF inhibitor toxicities: heart failure symptoms, neurologic symptoms, cytopenias 1

Additional Differential Considerations:

• Drug reaction with eosinophilia and systemic symptoms (DRESS) - check eosinophil count, liver enzymes 4
• Secondary syphilis - can present with palmar rash and scalp involvement; check RPR/TPPA
• Disseminated fungal infection - patient on immunosuppression; consider if systemic symptoms develop 1
• Psoriasis flare - AS patients have increased psoriasis risk, but timing suggests drug-induced 8

Monitoring Plan

Week 1-2:

• Daily self-monitoring for fever, worsening rash, mucosal involvement
• Return immediately if: fever >38°C, facial swelling, difficulty breathing, mucosal erosions

Week 2-4:

• Dermatology follow-up to assess response
• Repeat CBC, CRP/ESR
• If improving: continue topical therapy, taper corticosteroids over 4-6 weeks

Week 4-8:

• Once skin clear or near-clear: initiate alternative biologic for AS
• Close dermatologic monitoring during first 3 months of new biologic

Prognosis

With certolizumab discontinuation and appropriate topical therapy, expect:

• Palmar pustules: improvement within 2-4 weeks 3
• Trunk/limb rash: improvement within 2-6 weeks 2
• Scalp dermatitis: may take 4-8 weeks 2

Complete resolution typically occurs within 2-3 months of drug cessation 3, 2.